{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:48:54Z","timestamp":1783021734904,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jbo.2019.100252","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T11:33:12Z","timestamp":1563276792000},"page":"100252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials"],"prefix":"10.1016","volume":"18","author":[{"given":"Antonio","family":"Galvano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Scaturro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Incorvaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cusenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Cutaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Guadagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Roselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Adelfio","family":"Latteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia Mauro","family":"Giulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jbo.2019.100252_bib0001","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"issue":"16","key":"10.1016\/j.jbo.2019.100252_bib0002","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/jnci\/djn233","article-title":"Residual risk of breast cancer recurrence 5 years after adjuvant therapy","volume":"100","author":"Brewster","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.jbo.2019.100252_bib0003","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results","volume":"172","author":"Roehl","year":"2004","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.jbo.2019.100252_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","article-title":"EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease","volume":"59","author":"Heidenreich","year":"2011","journal-title":"Eur. Urol."},{"issue":"Suppl 5","key":"10.1016\/j.jbo.2019.100252_bib0005","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.jbo.2019.100252_bib0006","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jbo.2019.100252_bib0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.acuro.2011.03.011","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"35","author":"Mottet","year":"2011","journal-title":"Actas Urol. Esp."},{"issue":"2","key":"10.1016\/j.jbo.2019.100252_bib0008","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.thorsurg.2014.12.003","article-title":"National comprehensive cancer network (NCCN) clinical practice guidelines for lung cancer screening","volume":"25","author":"Wood","year":"2015","journal-title":"Thorac. Surg. Clin."},{"issue":"2","key":"10.1016\/j.jbo.2019.100252_bib0009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jbo.2019.100252_bib0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1020299707510","article-title":"Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database","volume":"76","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"issue":"Suppl 6","key":"10.1016\/j.jbo.2019.100252_bib0011","doi-asserted-by":"crossref","first-page":"vi12","DOI":"10.1093\/annonc\/mdr371","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Aebi","year":"2011","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.jbo.2019.100252_bib0012","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.jbo.2019.100252_bib0013","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2019.100252_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1188\/07.ONF.55-63","article-title":"Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer","volume":"34","author":"Limburg","year":"2007","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.jbo.2019.100252_bib0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.maturitas.2016.10.007","article-title":"Osteoporosis management in patients with breast cancer: EMAS position statement","volume":"95","author":"Tr\u00e9mollieres","year":"2017","journal-title":"Maturitas"},{"issue":"Suppl 6","key":"10.1016\/j.jbo.2019.100252_bib0016","doi-asserted-by":"crossref","first-page":"vi25","DOI":"10.1093\/annonc\/mdr372","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Cardoso","year":"2011","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2019.100252_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2019.100252_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2011.06.020","article-title":"A comparison of international breast cancer guidelines \u2013 do the national guidelines differ in treatment recommendations?","volume":"48","author":"Wolters","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.jbo.2019.100252_bib0019","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2019.100252_sbref0020","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011"},{"issue":"7303","key":"10.1016\/j.jbo.2019.100252_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jbo.2019.100252_bib0022","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.jbo.2019.100252_bib0023","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"30","key":"10.1016\/j.jbo.2019.100252_bib0024","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of Denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9992","key":"10.1016\/j.jbo.2019.100252_bib0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant Denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jbo.2019.100252_bib0026","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jbo.2019.100252_bib0027","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: anti-RANKL antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.jbo.2019.100252_bib0028","first-page":"130","article-title":"Bisphosphonates \u2013 mechanisms of action","author":"Martin","year":"2000","journal-title":"Exp. Clin. Pharmacol."},{"key":"10.1016\/j.jbo.2019.100252_bib0029","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.jbo.2019.100252_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191455","article-title":"Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: a systematic review and meta-analysis","volume":"13","author":"Hayes","year":"2018","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.jbo.2019.100252_bib0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/M16-2577","article-title":"Bone health and bone-targeted therapies for nonmetastatic prostate Cancer: a systematic review and meta-analysis","volume":"167","author":"Alibhai","year":"2017","journal-title":"Ann. Intern. Med."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213741930123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213741930123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:16:58Z","timestamp":1761941818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221213741930123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":31,"alternative-id":["S221213741930123X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2019.100252","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2019.100252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100252"}}